LOG IN TO YOUR PROFILE

Only Vets and Welfare organisations may search for Microchip numbers on the website. Simply log into your profiles to access the Search for a Microchip field.

DOWNLOAD THE VIRBAC BACKHOME AFRICA APP

Download the App from the App stores and simply log into your profiles to access the Search for a Microchip field. Only Vets and Welfare organisations may search for Microchip numbers on the App.

CALL +27 11 0278837 / 8528523

(Weekdays 8am - 5 pm only)

EMAIL

backhome@virbac.co.za

backhome.support.external@virbac.co.za

Virbac RSA is a veterinary pharmaceutical company concerning itself with the warehousing and manufacture of Act 36 liquids, tablets and pesticide products, secondary packaging (where applicable), marketing and distribution of veterinary products. Virbac RSA is one of the few GMP (Good Manufacture Practice) approved veterinary facilities in South Africa and maintains the high standard required by S.A.H.P.R.A. (South African Health Products Regulatory Authority) and other statutory bodies.

RESEARCH AND DEVELOPMENT

Research into new veterinary products and their development are at the heart of Virbac's R&D missions. Every day throughout the world, 230 men and women devote all their energy to fulfilling clients' needs and creating the products of tomorrow. In France, where the company has its biggest centre, R&D focuses on two main aspects. Firstly, biological R&D which develops biological products (vaccines, interferon’s, etc.) and, secondly, pharmaceutical R&D which develops all kinds of chemical-based pharmacological therapeutic products (anti-infective, internal and external parasiticides, anti-inflammatories, etc.) intended for all species of animal.

Internationally, the skills of the R&D teams are focused on local markets where Virbac is very well represented. In the United States, too, particular attention is being paid to the development of parasiticides and antibiotics for companion animals. In India, the whole range of medicines for food producing animals is a key objective.

SUBSCRIBE TO OUR NEWSLETTER